Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Heart failure affects an estimated 64.3 million people worldwide
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Subscribe To Our Newsletter & Stay Updated